Figure 6.
Fastuosain treatment (intraperitoneally, for 21 days) of GFP-chimeric C57Bl/6 mice injected intravenously with B16F10-Nex2 melanoma cells. GFP-chimeric mice were treated with fastuosain and challenged intravenously with B16F10-Nex2 cells (105). (A) Metastatic lung nodules; (B) double-labeled (GFP+, MHC class II+) cell migration to the lungs of chimeric mice. *P < .05.